FUNDING

New investment will allow Cytomos to drive sales of its first commercial product, Celledonia™, built on its cell-analysis technology platform AuraCyt, which is already generating significant market traction.

With this funding, TactoTek will accelerate the adoption of IMSE globally by expanding customer-facing operations and streamlining IMSE solution design by augmenting our software-based delivery system with AI elements and plug-ins for CAD and simulation packages

“GPx’s innovative approach to heart monitoring and chronic disease management is a perfect fit for the NEC Group’s vision of leveraging advanced technology to improve quality of life,” said Shintaro Matsumoto, President and CEO of NEC X. “By joining forces with GPx, we aim to enhance their predictive algorithms and capabilities. Together, we can transform the healthcare industry.”

Derek Herrera, founder and CEO of Bright Uro. “With this funding, we are well resourced for the launch of Glean in 2025, while also continuing to resource our pipeline of innovation. We have never been more confident in the expected impact Glean will have for clinicians and millions of patients suffering from urinary issues.”

The funding will accelerate the commercialization of the Nuclera eProtein Discovery platform, to optimize protein expression and purification workflows within research labs globally

Michael Harris, Chief Executive Officer of Biocomposites, said: “Periprosthetic joint infection is a large and growing problem worldwide. Quickly and accurately pinpointing the bacteria that cause each infection is essential if patients are to receive the best care and maximise their chances of full recovery.